RCEL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
26.1M
+20.3%
21.7M
+12.7%
19.3M
+9.3%
17.6M
+3.2%
17.1M
Cost of Revenue
4.2M
+6.0%
3.9M
+11.7%
3.5M
+6.6%
3.3M
+3.7%
3.2M
Gross Profit
21.9M
+23.5%
17.8M
+13.0%
15.7M
+9.9%
14.3M
+3.1%
13.9M
Operating Expenses
24.6M
-0.2%
24.6M
+0.4%
24.5M
-0.8%
24.7M
+7.3%
23.0M
R&D
4.7M
-7.5%
5.1M
-9.8%
5.6M
-1.1%
5.7M
+51.8%
3.7M
SG&A
19.9M
+1.7%
19.5M
+3.4%
18.9M
-0.7%
19.0M
-1.3%
19.3M
Operating Income
-2629000
+61.6%
-6855000
+22.1%
-8803000
+15.4%
-10408000
-13.7%
-9153000
EBITDA
-2037000
+67.4%
-6250000
+23.6%
-8176000
+15.8%
-9708000
-13.2%
-8579000
Net Income
-6222000
+18.8%
-7663000
+27.8%
-10611000
+8.7%
-11621000
+11.9%
-13187000
EPS (Basic)
$-0.20
+20.0%
$-0.25
+28.6%
$-0.35
+7.9%
$-0.38
+17.4%
$-0.46
EPS (Diluted)
$-0.20
+20.0%
$-0.25
+28.6%
$-0.35
+7.9%
$-0.38
+17.4%
$-0.46
Shares (Diluted)
30.9M
+0.4%
30.7M
+0.7%
30.5M
+0.4%
30.4M
+7.2%
28.4M
Avita Medical (RCEL) — Financials